Biography for Nick Paul Taylor
Nick Taylor, UK Correspondent
Nick Taylor is a freelance journalist with more than six years' experience of reporting on the global biopharma industry. Since graduating with a biology degree from the University of York, Nick has written for numerous healthcare publications, including Nature BioPharma Dealmakers, Life Science Leader and Outsourcing-Pharma. You can contact him at firstname.lastname@example.org and follow him on Twitter at @NickPaulTaylor.
Articles by Nick Paul Taylor
The team behind a planned 10,000-person, 265,000-square-meter cancer research and care hub in London is looking for software developers to occupy some of the site. By housing software companies, biotechs, med-tech developers and other companies in part of the U.K.'s cancer research and care network, the team is aiming to better connect the public and private sectors.
Roche is reportedly considering continuing its sequencing dealmaking activity with a bid for Pacific Biosciences.
Bavarian Nordic has signed up to work with Evaxion Biotech on the development of a vaccine against methicillin-resistant Staphylococcus aureus (MRSA). The project is underpinned by Eden Technology, an in silico vaccine discovery platform that combines data, algorithms and deep learning to unearth antigens.
Jonathan Rothberg, the Yale University entrepreneur who set up 454 Life Sciences and Ion Torrent, has raised $40 million to bankroll his next venture, a tech-enabled drug discovery shop. The startup, LAM Therapeutics, is aiming to leverage advances in genome editing, sequencing, computer science and artificial intelligence to make drug discovery cheaper and more precise.
Illumina has signed deals to genotype the sample collections at four biobanks. Each of the projects is aiming to build a repository of linked genotypic and phenotypic data, with the sequencing results generated by Illumina being paired to electronic medical records (EMRs) possessed by the owners of the biobanks.
Stallergenes Greer has resumed production at its plant that was blighted by IT problems. The restart of manufacturing comes nearly two months after regulators found the IT system introduced at the site in August was causing operational disruptions and erroneous product deliveries.
AstraZeneca has outlined how it is using the white-hot CRISPR genome editing technology to put its repositories of sequencing data to work in its R&D programs. The initiative is one of the many ways in which AstraZeneca is applying the technology at its drug discovery and development units.
DNAnexus has connected its genomics platform to Sapio Sciences' Exemplar laboratory information management system (LIMS). The integration is expected to provide clients with a sample-to-answer tracking system, a resource the collaborators see cutting costs while improving quality control.
The division, which the company has set up to meet rising demand for postapproval research, will make use of BioClinica's technology capabilities.
CosmosID has raised $6 million to advance its microbiome software business. The Series B round is intended to enable CosmosID to build out and enhance multiple aspects of its operation, with the expansion of engineering capabilities and improvement of genotype-phenotype linkage abilities high on its agenda.